Recombinant human uPA protein (ab167714)

Our Abpromise guarantee covers the use of ab167714 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Biological activity

Measured by its ability to cleave a peptide substrate, N - carbobenzyloxy - Gly - Gly - Arg - 7 - amido - 4 - methylcoumarin (Z - GGR - AMC). The specific activity is > 2000 pmoles/min/µg.
Applications

SDS-PAGE

Functional Studies
Endotoxin level

< 1.000 Eu/µg
Purity

>95% by SDS-PAGE .
Form

Lyophilised
Concentration information loading...

Stability and Storage

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

pH: 7.40
Constituent: 99% PBS
Note: Normally Mannitol or Trehalose are added as protectants before lyophilization.

This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitution

It is recommended to reconstitute the lyophilized protein in 50µl sterile deionized water to a final concentration of 1mg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage.

Alternative names
- ATF
- BDPLT5
- EC 3.4.21.73
- PLAU
- QPD
- u PA
- U plasminogen activator
- u-PA
- UPA
- UPAM
- Urinary plasminogen activator
- URK
- Urokinase plasminogen activator
- Urokinase type plasminogen activator
see all
Relevance

Urokinase type plasminogen activator (uPA) is secreted from cells as a precursor which is activated to the two chain form consisting of an A and B chain. The active high MW form is further processed by removal of an amino terminal fragment to an active low MW form (35 kDa). uPA is a serine protease that activates plasminogen toplasmin. High levels of uPA and plasminogen activator inhibitor type 1 (PAI 1) in breast cancer tissue extracts have been associated with rapid disease progression. The malignant phenotype of prostatic tumor cells correlates with the expression of both uPA and its cell membrane receptor (uPAR).

SDS-PAGE - Recombinant human uPA protein (ab167714)

SDS-PAGE of reduced ab167714 stained overnight with Coomassie Blue.
DTT-reduced Protein migrates as three bands corresponding to the long α chain, β chain and unprocessed full-length chain with the molecular mass of 18 kDa, 32 kDa and 50 kDa respectively due to glycosylation and cleavage.

ab167714 has not yet been referenced specifically in any publications.

Publishing research using ab167714? Please let us know so that we can cite the reference in this datasheet.

Customer reviews and Q&As